File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of extended lamivudine therapy in asian patients with chronic hepatitis B

TitleEffects of extended lamivudine therapy in asian patients with chronic hepatitis B
Authors
Issue Date2000
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Gastroenterology, 2000, v. 119 n. 1, p. 172-180 How to Cite?
AbstractBackground and Aims: One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. However, the effects of prolonged therapy are unknown. Methods: A total of 334 Asian patients with chronic hepatitis B from a previously reported 1-year study were randomized to receive either lamivudine (100 or 25 mg) or placebo for another year. The effects of treatment on serum HBV-DNA suppression, alanine transaminase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion were measured. The presence of YMDD variant HBV and its effect were also determined. Results: A significantly greater proportion of patients achieved sustained HBV-DNA suppression and ALT normalization with 100 mg lamivudine daily for 2 years compared with lamivudine for 1 year followed by placebo for the second year (P < 0.001). Daily lamivudine therapy for 2 years was safe and resulted in incremental HBeAg seroconversion from 17% at week 52 to 27% at week 104. HBeAg seroconversion during continued lamivudine therapy increased linearly with increasing pretherapy ALT levels (P < 0.001). Despite the emergence of YMDD mutant in 38% of the patients, they continued to clear rum HBeAg and maintain lower median serum HBV-DNA and ALT levels than baseline values. In contrast, ALT levels increased 8-12 weeks after switching from lamivudine to placebo, but returned to normal once lamivudine treatment was resumed. Conclusions: Treatment with lamivudine for 2 years is both well tolerated and efficacious in patients with chronic hepatitis B.
Persistent Identifierhttp://hdl.handle.net/10722/162436
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLiaw, YFen_US
dc.contributor.authorLeung, NWYen_US
dc.contributor.authorChang, TTen_US
dc.contributor.authorGuan, Ren_US
dc.contributor.authorTai, DIen_US
dc.contributor.authorNg, KYen_US
dc.contributor.authorChien, RNen_US
dc.contributor.authorDent, Jen_US
dc.contributor.authorRoman, Len_US
dc.contributor.authorEdmundson, Sen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:19:54Z-
dc.date.available2012-09-05T05:19:54Z-
dc.date.issued2000en_US
dc.identifier.citationGastroenterology, 2000, v. 119 n. 1, p. 172-180en_US
dc.identifier.issn0016-5085en_US
dc.identifier.urihttp://hdl.handle.net/10722/162436-
dc.description.abstractBackground and Aims: One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. However, the effects of prolonged therapy are unknown. Methods: A total of 334 Asian patients with chronic hepatitis B from a previously reported 1-year study were randomized to receive either lamivudine (100 or 25 mg) or placebo for another year. The effects of treatment on serum HBV-DNA suppression, alanine transaminase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion were measured. The presence of YMDD variant HBV and its effect were also determined. Results: A significantly greater proportion of patients achieved sustained HBV-DNA suppression and ALT normalization with 100 mg lamivudine daily for 2 years compared with lamivudine for 1 year followed by placebo for the second year (P < 0.001). Daily lamivudine therapy for 2 years was safe and resulted in incremental HBeAg seroconversion from 17% at week 52 to 27% at week 104. HBeAg seroconversion during continued lamivudine therapy increased linearly with increasing pretherapy ALT levels (P < 0.001). Despite the emergence of YMDD mutant in 38% of the patients, they continued to clear rum HBeAg and maintain lower median serum HBV-DNA and ALT levels than baseline values. In contrast, ALT levels increased 8-12 weeks after switching from lamivudine to placebo, but returned to normal once lamivudine treatment was resumed. Conclusions: Treatment with lamivudine for 2 years is both well tolerated and efficacious in patients with chronic hepatitis B.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_US
dc.relation.ispartofGastroenterologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAsian Continental Ancestry Groupen_US
dc.subject.meshDna, Viral - Antagonists & Inhibitors - Blooden_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshEthnic Groupsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B E Antigens - Analysis - Geneticsen_US
dc.subject.meshHepatitis B Virus - Geneticsen_US
dc.subject.meshHepatitis C, Chronic - Blood - Drug Therapy - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLamivudine - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMutationen_US
dc.subject.meshReference Valuesen_US
dc.subject.meshReverse Transcriptase Inhibitors - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshSerologic Testsen_US
dc.titleEffects of extended lamivudine therapy in asian patients with chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1053/gast.2000.8559-
dc.identifier.pmid10889166-
dc.identifier.scopuseid_2-s2.0-0034235528en_US
dc.identifier.hkuros50576-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034235528&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume119en_US
dc.identifier.issue1en_US
dc.identifier.spage172en_US
dc.identifier.epage180en_US
dc.identifier.isiWOS:000088108800023-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLiaw, YF=7202451038en_US
dc.identifier.scopusauthoridLeung, NWY=26643107200en_US
dc.identifier.scopusauthoridChang, TT=7404725147en_US
dc.identifier.scopusauthoridGuan, R=7102456913en_US
dc.identifier.scopusauthoridTai, DI=7005048694en_US
dc.identifier.scopusauthoridNg, KY=7403178546en_US
dc.identifier.scopusauthoridChien, RN=12787728600en_US
dc.identifier.scopusauthoridDent, J=7201577625en_US
dc.identifier.scopusauthoridRoman, L=7101826288en_US
dc.identifier.scopusauthoridEdmundson, S=15723166300en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats